Direct Costs of Carcinoid Syndrome Diarrhea among Adults in the United States

**CORE TIP**

Healthcare resource use and costs among patients with carcinoid syndrome (CS) are known to be high, but the incremental burden of CS diarrhea (CSD) is less well understood. We analyzed insured, working age CS patients with and without CSD using the MarketScan® database (2014-2016) and observed a greater economic burden in the presence of CSD. Patients with CSD required more healthcare resources than their peers without CSD, including hospitalizations (44% vs. 25%) and Emergency Department visits (55% vs. 31%). Total adjusted mean annual costs per patient were 50% higher (+$25,865), driven largely by the use of more outpatient services (+56%).